middle.news
Actinogen Secures $4.3m Boost for Alzheimer’s Trial Ahead of Key Data
9:10am on Tuesday 27th of January, 2026 AEDT
•
Biotechnology
Read Story
Actinogen Secures $4.3m Boost for Alzheimer’s Trial Ahead of Key Data
9:10am on Tuesday 27th of January, 2026 AEDT
Key Points
Secured $4.3 million second tranche of non-dilutive R&D tax funding
Funding supports XanaMIA Phase 2b/3 Alzheimer’s disease trial and open-label extension
Trial fully enrolled across 35 sites in Australia and the US
Interim analysis expected late January 2026; topline results due November 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Actinogen Medical (ASX:ACW)
OPEN ARTICLE